- Poster presentation
- Open Access
Pentoxifylline therapy among preterm neonates <1,500 g in reducing mortality from neonatal sepsis: a double-blind, randomized placebo-controlled trial
© Sareno and Mantaring; licensee BioMed Central Ltd. 2013
- Published: 5 November 2013
- Adverse Drug Reaction
- Preterm Infant
- Neonatal Sepsis
Pentoxifylline, a xanthine derivative, has raised new interest in neonatal research due to its immunomodulatory functions and its potential role in reducing mortality from sepsis. Two small studies on a per-protocol analysis have shown promising results. This larger trial on an intention-to-treat basis will determine whether the use of pentoxifylline as an adjunctive therapy for sepsis in preterm neonates (≤36 weeks) weighing <1,500 g will truly result in a reduction in the all-cause mortality.
Preterm infants ≤1,500 g with suspected infection admitted to the NICU of a large tertiary, training, government hospital were eligible for inclusion in the study. After informed consent, they were randomized to receive either pentoxifylline at a dose of 6 mg/kg/hour or placebo. Patients with major congenital malformations, congenital infections and severe hemorrhage were excluded from the study. Pentoxifylline was administered as a 6 ml infusion for 6 hours for 6 days. The control group received normal saline in the same manner as the pentoxifylline infusion. Patients, parents and physicians (outcome assessors) were blinded to the treatment assignments. The primary outcome was analyzed on an intention to treat basis. The primary outcome measured in the study is the occurrence of all-cause mortality between the two groups. Secondary outcomes measured include mortality from sepsis, adverse drug reactions and length of hospital stay.
A total of 312 neonates are included in this interim analysis: 156 in the pentoxifylline group and 156 in the control group. Baseline characteristics were comparable between the two groups. In this analysis, there is no difference in the occurrence of death among patients in the pentoxifylline group versus the placebo group (RR: 1.08 (0.83, 1.41)). There is no statistical difference in the risk of death from septic shock (RR: 1.03 (0.67, 1.59), P = 1.0). There was also no significant difference in the length of hospital stay in the two groups (36 days in treatment group vs. 35 days in control group, P = 0.910). No significant adverse drug reactions were noted with pentoxifylline use.
Pentoxifylline as an adjunct therapy for sepsis did not show a decrease in the all-cause mortality. There is also no difference in the occurrence of death from sepsis and length of hospital stay. No adverse drug reactions were noted with pentoxifylline.
The authors thank the neonatology fellows of the Philippine General Hospital and Ms Carmi Pitajen, RN, research assistant.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.